Quest Diagnostics

Report Status: Final

Patient Information	Specimen Information	Client Information
DOB: **AGE:** Gender: Phone: Patient ID:	Specimen: Requisition: Lab Ref #: Collected: Received: Reported:	

COMMENTS: FASTING:YES

Test Name	In Range	Out Of Range	Reference Range	Lab
MICROALBUMIN, RANDOM URINE (W/CREATININE)				
CREATININE, RANDOM URINE	88		20-320 mg/dL	
MICROALBUMIN, RANDOM URINE (W/CREATININE)				
MICROALBUMIN	0.6 Reference Range Not established		mg/dL	
MICROALBUMIN/CREATININE RATIO, RANDOM URINE	7		<30 mcg/mg creat	
The ADA defines abnormalities in albumin excretion as follows:				
Category / Result (mcg/mg creatinine)				
Normal	<30			
Microalbuminuria	30-299			
Clinical albuminuria	> OR = 300			
The ADA recommends that at least two of three specimens collected within a 3-6 month period be abnormal before considering a patient to be within a diagnostic category.				
COMPREHENSIVE METABOLIC PANEL				
GLUCOSE		**353 H**	65-99 mg/dL Fasting reference interval	
For someone without known diabetes, a glucose value >125 mg/dL indicates that they may have diabetes and this should be confirmed with a follow-up test.				
UREA NITROGEN (BUN)	8		7-25 mg/dL	
CREATININE	0.96		0.60-1.35 mg/dL	
eGFR NON-AFR. AMERICAN	98		> OR = 60 mL/min/1.73m2	
eGFR AFRICAN AMERICAN	114		> OR = 60 mL/min/1.73m2	
BUN/CREATININE RATIO	NOT APPLICABLE		6-22 (calc)	
SODIUM	136		135-146 mmol/L	
POTASSIUM	4.1		3.5-5.3 mmol/L	
CHLORIDE	98		98-110 mmol/L	
CARBON DIOXIDE	26		20-32 mmol/L	
CALCIUM	9.7		8.6-10.3 mg/dL	
PROTEIN, TOTAL	7.1		6.1-8.1 g/dL	
ALBUMIN	4.0		3.6-5.1 g/dL	
GLOBULIN	3.1		1.9-3.7 g/dL (calc)	
ALBUMIN/GLOBULIN RATIO	1.3		1.0-2.5 (calc)	
BILIRUBIN, TOTAL	0.7		0.2-1.2 mg/dL	
ALKALINE PHOSPHATASE	52		40-115 U/L	
AST	13		10-40 U/L	
ALT	14		9-46 U/L	

Patient Information	Specimen Information	Client Information
DOB: **AGE:** Gender: Patient ID:	Specimen: Collected: Received: Reported:	

Test Name	In Range	Out Of Range	Reference Range	Lab
HEMOGLOBIN A1c		**>14.0 H**	<5.7 % of total Hgb	
		Verified by repeat analysis.		

For someone without known diabetes, a hemoglobin A1c value of 6.5% or greater indicates that they may have diabetes and this should be confirmed with a follow-up test.

For someone with known diabetes, a value <7% indicates that their diabetes is well controlled and a value greater than or equal to 7% indicates suboptimal control. A1c targets should be individualized based on duration of diabetes, age, comorbid conditions, and other considerations.

Currently, no consensus exists regarding use of hemoglobin A1c for diagnosis of diabetes for children.

CBC (INCLUDES DIFF/PLT)			
WHITE BLOOD CELL COUNT	4.4		3.8-10.8 Thousand/uL
RED BLOOD CELL COUNT	4.35		4.20-5.80 Million/uL
HEMOGLOBIN		**11.7 L**	13.2-17.1 g/dL
HEMATOCRIT		**37.1 L**	38.5-50.0 %
MCV	85.3		80.0-100.0 fL
MCH		**26.9 L**	27.0-33.0 pg
MCHC		**31.5 L**	32.0-36.0 g/dL
RDW	11.9		11.0-15.0 %
PLATELET COUNT	230		140-400 Thousand/uL
MPV	11.5		7.5-12.5 fL
ABSOLUTE NEUTROPHILS	1980		1500-7800 cells/uL
ABSOLUTE LYMPHOCYTES	1870		850-3900 cells/uL
ABSOLUTE MONOCYTES	449		200-950 cells/uL
ABSOLUTE EOSINOPHILS	79		15-500 cells/uL
ABSOLUTE BASOPHILS	22		0-200 cells/uL
NEUTROPHILS	45		%
LYMPHOCYTES	42.5		%
MONOCYTES	10.2		%
EOSINOPHILS	1.8		%
BASOPHILS	0.5		%
URINALYSIS, COMPLETE			
COLOR	YELLOW		YELLOW
APPEARANCE	CLEAR		CLEAR
SPECIFIC GRAVITY	1.027		1.001-1.035
PH	< OR = 5.0		5.0-8.0
GLUCOSE		**3+**	NEGATIVE
BILIRUBIN	NEGATIVE		NEGATIVE
KETONES		**1+**	NEGATIVE
OCCULT BLOOD	NEGATIVE		NEGATIVE
PROTEIN	NEGATIVE		NEGATIVE
NITRITE	NEGATIVE		NEGATIVE
LEUKOCYTE ESTERASE	NEGATIVE		NEGATIVE
WBC	NONE SEEN		< OR = 5 /HPF
RBC	NONE SEEN		< OR = 2 /HPF
SQUAMOUS EPITHELIAL CELLS	NONE SEEN		< OR = 5 /HPF
BACTERIA	NONE SEEN		NONE SEEN /HPF
HYALINE CAST	NONE SEEN		NONE SEEN /LPF

Patient Information	Specimen Information	Client Information
DOB: **AGE:** Gender: Patient ID:	Specimen: Collected: Received: Reported:	

Test Name	In Range	Out Of Range	Reference Range	Lab
C-PEPTIDE	0.90		0.80-3.85 ng/mL	
INSULIN	4.7		2.0-19.6 uIU/mL	

This insulin assay shows strong cross-reactivity for some insulin analogs (lispro, aspart, and glargine) and much lower cross-reactivity with others (detemir, glulisine).

PERFORMING SITE: